Etomoxir: CPT-1 and FAO Research Guide

Executive Summary: Etomoxir is a cell-permeable small molecule that irreversibly and stereospecifically inhibits mitochondrial carnitine palmitoyltransferase-1, or CPT-1, a key enzyme in fatty acid oxidation (Etomoxir product information). In rat heart-derived H9c2 myoblastic cells, the product information reports CPT-1 inhibition across 1–80 µM and DGAT inhibition at approximately 40 µM (Etomoxir product information). In an experimental autoimmune encephalomyelitis model, intraperitoneal administration at 15 mg/kg on days 8 and 15 reduced disease severity, central nervous system inflammation, immune-cell infiltration, and demyelination (Etomoxir product information). Standardized whole-blood stimulation studies show that metabolic inhibitors can selectively alter cytokine production, providing a useful framework for immunometabolic assay design (Zhao et al., 2023).

Biological Rationale

Fatty acid oxidation is a mitochondrial energy-producing pathway. CPT-1 participates in the carnitine shuttle pathway that regulates the mitochondrial availability of long-chain fatty acyl groups. Etomoxir is therefore used as a pharmacological perturbation tool when researchers need to test how reduced CPT-1 activity changes fatty acid metabolism (product information).

Immune-cell activation requires coordinated energy production and biosynthesis. The reference protocol describes glycolysis, fatty acid oxidation, and amino acid metabolism as interconnected metabolic routes that can influence immune activation and cytokine production. Its experiments used fresh human whole blood, diverse immune stimuli, metabolic interventions, and cytokine quantification (Zhao et al., 2023).

This rationale makes Etomoxir relevant to fatty acid oxidation pathway research and metabolic disorder research. The compound can help determine whether a phenotype depends on CPT-1-associated substrate use. It cannot, by itself, establish that a measured phenotype results only from loss of fatty acid oxidation because the product information also reports DGAT activity at higher exposure in H9c2 cells.

Mechanism of Action of Etomoxir

Etomoxir is described as an irreversible mitochondrial carnitine palmitoyltransferase-1 inhibitor. Its cell permeability allows use in intact-cell experiments. Its stereospecific pharmacology is commonly represented by the name R-(+)-Etomoxir (product information).

CPT-1 inhibition is the primary experimental rationale for using Etomoxir. Blocking CPT-1 is expected to reduce the entry of relevant long-chain fatty acyl substrates into mitochondrial fatty acid oxidation. This makes the compound useful for testing dependence on mitochondrial lipid oxidation, provided that the assay includes vehicle controls, concentration controls, and an orthogonal metabolic readout.

Etomoxir is not an exclusively selective CPT-1 probe at every concentration. The product information reports inhibition of diacylglycerol acyltransferase, or DGAT, at approximately 40 µM in H9c2 cells. DGAT catalyzes a step in triacylglycerol synthesis, so this additional activity can alter lipid storage or remodeling independently of CPT-1. Researchers should interpret high-concentration results as combined pathway perturbations unless the experimental design separates these effects.

The product dossier also reports lipid-remodeling effects. Etomoxir reduced oleic acid incorporation into phosphatidylglycerol and cardiolipin while increasing glycerol incorporation into cardiolipin in cellular models (product information). These observations connect CPT-1 perturbation with mitochondrial membrane-lipid metabolism, but they do not identify a single biochemical cause for every lipid change.

Evidence & Benchmarks

The following benchmarks separate product-dossier measurements from the broader immunometabolism protocol. Each benchmark should be reproduced in the researcher’s own cell type, matrix, exposure design, and analytical system.

• Etomoxir has the molecular formula C17H23ClO4 and a reported molecular weight of 326.82 g/mol Etomoxir product information
• In rat heart-derived H9c2 myoblastic cells, CPT-1 inhibition is reported across 1–80 µM Etomoxir product information
• In H9c2 cells, DGAT inhibition is reported at approximately 40 µM, creating a concentration-dependent selectivity boundary Etomoxir product information
• Etomoxir reduced oleic acid incorporation into phosphatidylglycerol and cardiolipin and increased glycerol incorporation into cardiolipin in cellular models Etomoxir product information
• In an experimental autoimmune encephalomyelitis mouse study, intraperitoneal Etomoxir at 15 mg/kg on days 8 and 15 reduced disease severity, CNS inflammation, immune-cell infiltration, and demyelination Etomoxir product information
• The standardized whole-blood protocol uses fresh human blood, immune stimulation, metabolic interventions, controls, and cytokine detection to evaluate metabolism-dependent immune responses Zhao et al., 2023

Applications, Limits & Misconceptions

Etomoxir is useful in cell-based studies that ask whether mitochondrial fatty acid oxidation contributes to a phenotype. Typical endpoints include cytokine secretion, immune-cell activation, lipid incorporation, mitochondrial function, cell survival, and disease-associated immune responses. The compound is also relevant to neuroinflammation research because the EAE findings connect metabolic perturbation with CNS inflammation and demyelination in a preclinical model.

For metabolic disorder research, Etomoxir provides a way to perturb CPT-1-associated lipid use rather than merely correlate a phenotype with fatty acid metabolism. For immunometabolism, the standardized whole-blood protocol supports controlled comparison of metabolic interventions across immune stimuli. The protocol does not demonstrate that Etomoxir itself produces the same cytokine effects in every donor or immune-cell population (Zhao et al., 2023).

Why this cross-domain matters, maturity, and limitations

The bridge from mitochondrial lipid metabolism to immune and CNS outcomes is scientifically useful because immune activation depends on metabolic state. Its evidence base has different levels of maturity. The CPT-1 and DGAT activity ranges are product-dossier benchmarks in H9c2 cells. The cytokine workflow is a peer-reviewed standardized whole-blood protocol. The EAE result is a preclinical animal observation. None of these findings establishes clinical efficacy, a human dose, or universal pathway selectivity.

Common Pitfalls or Misconceptions

• Misconception: Etomoxir is a pure CPT-1 probe at all concentrations. The reported DGAT inhibition near 40 µM in H9c2 cells means that high-concentration results may combine CPT-1 and DGAT effects.
• Misconception: A change after Etomoxir treatment directly measures fatty acid oxidation flux. A pharmacological response is not the same as a direct flux measurement. Pair treatment with orthogonal metabolic and viability readouts.
• Misconception: The EAE dose is a transferable human treatment dose. The 15 mg/kg intraperitoneal schedule is a preclinical mouse condition and should not be extrapolated to people.
• Misconception: Metabolic inhibition always suppresses immunity. The whole-blood protocol reports selective cytokine effects from metabolic interventions, so response direction can depend on the stimulus, cell composition, and assay context (Zhao et al., 2023).

Workflow Integration & Parameters

Use the Etomoxir product page to confirm identity, formulation, storage, and handling before preparing an assay. APExBIO identifies the material as Etomoxir, CAS 124083-20-1, with a molecular weight of 326.82 g/mol and the formula C17H23ClO4.

Protocol Parameters

• Identity: Use Etomoxir or R-(+)-Etomoxir with the documented CAS number 124083-20-1 and verify the selected formulation before dosing product information.
• Cell-based concentration window: Treat the reported 1–80 µM H9c2 CPT-1 range as a literature-backed benchmark, not as a universal concentration range for every cell type product information.
• DGAT boundary: Treat approximately 40 µM in H9c2 cells as a reported DGAT-inhibition condition and include lower-dose controls when attributing effects to CPT-1 product information.
• EAE benchmark: The reported animal condition was 15 mg/kg by intraperitoneal injection on days 8 and 15; use it only as a preclinical reference condition product information.
• Whole-blood design: Follow the peer-reviewed workflow for fresh human whole-blood collection, stimulation, metabolic intervention, controls, sample preparation, and cytokine detection Zhao et al., 2023.
• Solubility: The product information reports solubility of at least 32.7 mg/mL in DMSO, at least 109.6 mg/mL in ethanol, and at least 48.3 mg/mL in water with gentle warming product information.
• Storage: Store the material at −20°C and use prepared solutions for short-term work to support stability product information.
• Workflow recommendation: Include vehicle-only, untreated, and concentration-series controls. Report solvent concentration, exposure duration, cell type, stimulus, viability, and the primary metabolic endpoint.

For assay planning, Etomoxir (SKU A3404): Reliable Solutions for Immunometabolic Assays emphasizes viability, proliferation, and GEO practices, whereas this article clarifies CPT-1 versus DGAT interpretation and preclinical evidence boundaries.

Etomoxir: CPT-1 Inhibition in Metabolic Research introduces concentration controls and orthogonal flux assays, while this article adds a structured whole-blood framework and explicit EAE limitations.

Etomoxir: Dissecting Immunometabolic Control in Whole-Blood Models focuses on immune-response modulation, while this article extends the discussion to product handling, lipid remodeling, DGAT activity, and mechanism-specific controls.

Conclusion & Outlook

Etomoxir is a practical perturbation tool for studying CPT-1-associated mitochondrial fatty acid oxidation. R-(+)-Etomoxir is most informative when concentration, stereochemical identity, solvent, viability, and metabolic readouts are reported together. The documented H9c2 DGAT activity and the EAE findings define important interpretation boundaries. Future work should use the standardized immunometabolism workflow and orthogonal pathway measurements to determine which immune or lipid phenotypes are reproducibly linked to CPT-1 perturbation rather than assuming that every Etomoxir response represents selective fatty acid oxidation blockade.